Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Aisling Capital is a venture capital firm founded in 2000 and headquartered in New York, NY. The firm has raised over $1.8 billion in committed capital across multiple funds, establishing itself as one of the longest-running dedicated healthcare private equity and venture capital firms. Aisling Capital focuses on investing in companies that develop and commercialize healthcare products, services, and technologies, addressing unmet medical needs.
The firm employs a team with extensive experience in the healthcare industry, which enhances its ability to identify promising investment opportunities. Aisling Capital has a strong track record of supporting both private and public companies within the life sciences sector. The firm operates from its New York office and has built a reputation for its strategic guidance and access to a broad network within the healthcare sector.
Aisling Capital invests primarily in the life sciences sector, which includes biotechnology, healthcare, medical devices, and pharma-tech. The firm targets companies at various stages of development, including seed, Series A, and growth equity. Their investment strategy encompasses a range of financial instruments, including seed and venture financing for development-stage companies, small-cap publicly traded equities, structured debt, royalty deals, and large-cap leveraged buyouts of profitable companies.
The firm seeks to partner with companies that are focused on developing and commercializing healthcare products and technologies that address significant medical needs. Aisling Capital's investment approach is driven by a thorough assessment of scientific, regulatory, financial, and commercial risks, ensuring that they back ventures with strong potential for success.
Aisling Capital's portfolio includes several notable companies within the healthcare sector:
This diverse portfolio reflects Aisling Capital's commitment to investing in innovative healthcare solutions that meet critical market needs.
Steven Elms: Managing Partner. Steven has extensive experience in healthcare investing and has led numerous successful investments in the sector.
Andrew Schiff, MD: Managing Partner. Andrew brings a medical background and has been instrumental in identifying promising healthcare ventures.
Eric Aguiar, MD: Partner. Eric has a strong track record in healthcare investments and provides valuable insights into clinical and regulatory matters.
Sunny Reddy: Principal. Sunny focuses on sourcing and evaluating new investment opportunities within the life sciences sector.
Wonpyo Yun: Principal. Wonpyo specializes in financial analysis and supports portfolio companies in achieving their growth objectives.
To pitch Aisling Capital, founders should submit their proposals through the contact information available on the firm's website. A comprehensive pitch deck should include details about the business model, market opportunity, competitive landscape, and team qualifications. Aisling Capital appreciates well-structured presentations that clearly articulate the startup's vision and potential.
Response times may vary, but founders can expect to hear back within a few weeks. A warm introduction from a mutual connection can enhance the chances of receiving a timely response.
In March 2023, Aisling Capital announced a new investment in Aimmune Therapeutics, Inc., which focuses on treatments for food allergies. This investment aligns with their strategy of supporting companies that address unmet medical needs in the healthcare sector.
In January 2023, Aisling Capital participated in a funding round for ADMA Biologics, Inc., further expanding their portfolio in the biopharmaceutical space. This investment underscores their commitment to advancing innovative healthcare solutions.
What are Aisling Capital's investment criteria?
Aisling Capital focuses on companies within the life sciences sector, including biotechnology, medical devices, and healthcare services. They invest in both private and public companies at various stages, from seed to growth equity.
How can founders apply or pitch to Aisling Capital?
Founders can reach out directly through the contact information provided on Aisling Capital's website. A well-prepared pitch deck that outlines the business model, market opportunity, and team is essential.
What makes Aisling Capital different from other venture firms?
Aisling Capital's extensive experience in the healthcare sector and its significant capital commitment set it apart. The firm has a long history of supporting healthcare innovation and offers strategic guidance to its portfolio companies.
What is Aisling Capital's geographic scope?
The firm primarily invests in North America, focusing on companies that are developing healthcare solutions that address unmet medical needs.
What is Aisling Capital's post-investment involvement like?
Aisling Capital provides strategic guidance and access to a broad network within the healthcare sector, helping portfolio companies navigate challenges and capitalize on opportunities.
What is the typical check size for investments?
Aisling Capital invests across a range of stages, with check sizes varying based on the company's development stage and specific needs. They engage in seed financing as well as larger growth equity investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.